[Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases]

Bull Cancer. 2010 Mar;97(3):301-10. doi: 10.1684/bdc.2010.1048.
[Article in French]

Abstract

From March 2003 to April 2004, were prospectively collected in France 1,289 ductal carcinoma in situ (DCIS) with data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30-84). DCIS was diagnosed by mammography in 87.6% of patients. Mastectomy (M), conservative surgery alone (CS) and conservative surgery with radiotherapy (CS + RT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients, respectively. Hormone therapy was administered to 13.4% of the patients. Nuclear grade was low in 21% of patients, intermediate in 38.5% and high in 40.5%. Excision was considered complete in 92% (CS) and 88.3% (CS + RT) of patients. Treatment modalities varied widely according to region: mastectomy rate, 20-37%; adjuvant RT, 84-96%; hormone treatment, 6-34%. Our survey on current DCIS management in France has highlighted correlations between pathological features (tumour size, margin, grade) and treatment options, with several similar variations to those observed in recent UK and US studies.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Axilla
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / therapy*
  • Carcinoma in Situ / pathology*
  • Carcinoma in Situ / therapy*
  • Carcinoma, Ductal, Breast / pathology*
  • Carcinoma, Ductal, Breast / therapy*
  • Cross-Sectional Studies
  • Female
  • France
  • Humans
  • Lymph Node Excision / statistics & numerical data
  • Mastectomy / statistics & numerical data
  • Middle Aged
  • Prospective Studies
  • Radiotherapy Dosage
  • Sentinel Lymph Node Biopsy / statistics & numerical data

Substances

  • Antineoplastic Agents, Hormonal